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Pulmonary arterial hypertension (PAH), is a fatal disease characterized by a pseudo-
malignant phenotype. We investigated the expression and the role of the receptor tyrosine
kinase Axl in experimental (i.e., monocrotaline and Su5416/hypoxia treated rats) and clinical
PAH. In vitro Axl inhibition by R428 and Axl knock-down inhibited growth factor-driven
proliferation and migration of non-PAH and PAH PASMCs. Conversely, Axl overexpression
conferred a growth advantage. Axl declined in PAECs of PAH patients. Axl blockage inhibited
BMP9 signaling and increased PAEC apoptosis, while BMP9 induced Axl phosphorylation.
Gas6 induced SMAD1/5/8 phosphorylation and ID1/ID2 increase were blunted by BMP
signaling obstruction. Axl association with BMPR2 was facilitated by Gas6/BMP9 stimulation
and diminished by R428. In vivo R428 aggravated right ventricular hypertrophy and dys-
function, abrogated BMPR2 signaling, elevated pulmonary endothelial cell apoptosis and loss.
Together, Axl is a key regulator of endothelial BMPR2 signaling and potential determinant
of PAH.
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Pulmonary arterial hypertension (PAH) is a life-threateningdisease characterized by progressive pulmonary vasculo-pathy usually culminating in right heart failure1. Vaso-
constriction, endothelial dysfunction, structural remodeling of
pulmonary arteries, and inflammation contribute to the pro-
gression of the disease2, which shares several features with
cancer3.
Aberrant regulation and signaling of the TAM family of
receptor tyrosine kinases (RTKs)—Tyro3, Axl, and Mer—are
tightly linked with cancer progression, metastasis, and
chemoresistance4–8. Axl is activated by binding to its sole ligand,
growth arrest-specific protein 6 (Gas6)9, and via ligand-dependent
and -independent dimerization as well as heterodimerization with
non-TAM receptors10–12. The physical association of AXL with
particular RTKs, characterized by cross-linking co-immunopreci-
pitation, implicates AXL-mediated signaling synergy in the
acquired resistance of several RTKs to specific receptor-targeted
inhibitors7,8,13. Axl plays an essential role in vascular endothelial
growth factor A (VEGF-A)/VEGF receptor (VEGFR) signaling12.
In endothelial cells (ECs), Axl activation modulates anti-apoptotic
effects, possibly through its association with specific integrin
complexes14. Axl is highly expressed in vascular smooth muscle
cells (SMCs), where it plays a protective role during vascular
injury15,16. Upregulation and secretion of Gas6 with subsequent
activation of Axl, is one of the hallmarks of vascular injury
response and vascular remodeling. Gas6-induced Axl signaling
contributes to the survival of human pulmonary arterial ECs
(hPAECs)15, increases SMC proliferation and migration, blocks
apoptosis17,18, and regulates SMC immune heterogeneity and
extracellular matrix remodeling19.
Both proteins have been reported to be upregulated and acti-
vated in various human malignancies, in which their expression is
tightly correlated with poor prognosis and increased invasiveness/
metastasis20. Inhibition of Axl kinase in multiple model systems
reduces cancer cell survival, enhances chemosensitivity, and
diminishes metastatic potential6. On another side, ablation of Axl,
a key regulator of innate immune response21, has been associated
with increased production of proinflammatory cytokines and
failure to clear neutrophils undergoing apoptosis, thus favouring
a tumor-promoting environment22,23.
We investigated the role of Gas6/Axl in PAH. Axl inhibition by
the small molecule inhibitor R428 markedly reduced human
pulmonary arterial SMC (hPASMC) proliferation and migration,
but prompted toxic effects in hPAECs. These effects were con-
firmed in vivo, as R428 aggravated experimental pulmonary
hypertension (PH) in rats. R428 elevated pro-inflammatory
responses, exacerbated EC apoptosis and loss, and abrogated
the bone morphogenetic protein receptor 2 (BMPR2) signaling
pathway. Axl expression markedly declined in blood outgrowth
endothelial cells (BOECs), in laser-assisted microdissected intra-
pulmonary vessels (MDVs), and in the pulmonary endothelium
of IPAH patients. Axl deletion or blockage reduced BMPR2-
related canonical SMAD signaling. Importantly, Axl and BMPR2
co-interacted in hPAECs, indicating a previously unrecognized
association between these two receptors. Taken together, our
studies demonstrate the protective role of Gas6/Axl in PAH and
highlight a novel liaison between Gas6/Axl and BMP/
BMPR2 signaling pathways.
Results
R428 inhibits proliferation and migration of PASMCs. The
expression of Axl was augmented in the lungs of Sugen 5416/
hypoxia (SuHOX) and monocrotaline (MCT) rat models, and
chronic-hypoxia mouse model of PH, as compared to controls
(Supplementary Fig. 1). As Axl expression was strongly induced
in pulmonary vessels (Supplementary Fig. 1g) and pulmonary
arterial smooth muscle cells (PASMCs) in experimental PH
(Supplementary Fig. 1h), we explored the functional effect of Axl
inhibition on hPASMC proliferation and migration using a
clinically tested small molecule inhibitor R428 (BGB324). Pre-
treatment with R428 dose-dependently inhibited growth factor-
induced proliferation and migration of both control and IPAH
hPASMCs (Fig. 1a–d and Supplementary Fig. 2a–d). An anti-
proliferative effect of R428 was confirmed by western blot ana-
lyses using cell cycle markers Cyclin D1 and p27 (Fig. 1e, f), and
by immunofluorescence staining using the proliferation marker
Ki67 (Fig. 1g, h). Lentiviral overexpression of Axl in hPASMCs
conferred a growth advantage and increased sensitivity to R428
compared with the expression of a control construct (Fig. 1i, j).
Importantly, reduction of Axl expression by lentiviral short
hairpin RNA abrogated sensitivity to R428 at 1 and 2.5 µM,
indicating that the inhibitory effect is mediated via Axl and not by
off-targets (Fig. 1i, k). Exogenous stimulation of Axl with
recombinant Gas6 did not increase hPASMC proliferation
(Supplementary Fig. 2e, f).
R428 inhibits proliferation and induces apoptosis of PAECs.
Next we investigated the impact of R428 on human pulmonary
arterial endothelial cells (hPAECs) in vitro. An apparent reduc-
tion in epidermal growth factor (EGF)-induced proliferation was
observed for R428 pre-treated cells (Fig. 2a). Importantly, R428
induced both hPAEC cytotoxicity (Fig. 2b, c) and apoptotic cell
death at the nanomolar range (Fig. 2d, e and Supplementary
Fig. 3a). Remarkably, the IPAH-PAECs showed a stronger
cytotoxic response in comparison to donor non-PAH PAECs
(Fig. 2b, c). The cytotoxic effects in hPASMCs have been seen
with high doses of R428 (Supplementary Fig. 3c, d). The R428
initiated apoptosis was strongly inhibited by Gas6 stimulation,
supporting an anti-apoptotic role of Gas6 in vascular cells
(Supplementary Fig. 3e).
Endothelial expression of adhesion molecules is one of the
characteristic features of vascular dysfunction and damage24,25.
Thus, next we aimed to investigate the effect of Axl blockage on
markers of endothelial dysfunction and damage/vascular injury in
hPAECs. R428 treatment and Axl knock-down each substantially
increased mRNA levels of intercellular adhesion molecule 1
(ICAM1) (Fig. 2f, h). Interestingly, R428 treatment and Axl
deletion provided opposing results on the expression of vascular
cell adhesion molecule 1 (VCAM1), indicating that small
molecule inhibitor R428 and Axl deletion might contribute to
non-overlapping molecular pathways (Fig. 2g, h). R428 also
initiated a dose-dependent increase in ICAM1 mRNA expression
in hPASMCs, suggesting that Axl may regulate the immune
activation of SMCs (Supplementary Fig. 3f). Furthermore, R428
treatment of cultured hPAECs resulted in a significant and time-
dependent increase in endothelial monolayer permeability, as
demonstrated through the use of fluorescein isothiocyanate-
dextran (FITC-Dextran) transwell assays (Supplementary
Fig. 3g).
R428 aggravates experimental PH. MCT and SuHOX rat models
of PH developed evident RV hypertrophy (Fig. 3a, f). As compared
to controls, animals receiving R428 had more severe RV hyper-
trophy (Fig. 3a, f), augmented right ventricular systolic pressure
(RVSP) (Fig. 3b, g), impaired cardiac output (Fig. 3c, h), and
worsened tricuspid annular plane systolic excursion (Fig. 3d, i),
and a significantly increased total pulmonary vascular resistance
index (Fig. 3e, j). No changes in the systemic arterial pressure and
heart rate were noted after R428 application.
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R428 targets apoptosis, inflammation, and autoimmunity in
experimental PH. To understand the mechanism underlying the
detrimental effect of Axl inhibition in experimental PH, several
key processes associated with the pathogenesis of PAH and Axl
signaling26–29 were investigated. R428 increased Caspase-3
activity in SuHOX and MCT rat lung tissue (Fig. 4a, b and
Supplementary Fig. 4a, b) and SuHOX pulmonary vessel ECs
(Fig. 4c). A robust increase in p53 protein and its downstream
target p21 was noted after R428 treatment in both SuHOX and
MCT rat lungs (Fig. 4a, d, e and Supplementary Fig. 4a, c, d).
R428 also increased phosphatidylserine levels and anti-cardiolipin
IgG in plasma of SuHOX rats compared with vehicle-treated and
NOX controls, respectively, indicating the activation of apoptotic
signals (Fig. 4f, g). The inflammatory markers nitrotyrosine and
phospho-signal transducer and activator of transcription 3
(phospho-STAT3) and mRNAs of interferon gamma (IFN-γ) and
interleukin-6 (IL-6) were increased in the lungs of rats receiving
R428 compared with the vehicle-treated control rats (Fig. 4h, i, k, l
and Supplementary Fig. 5a, c, d). Furthermore, the expression of
IFN-γ-induced neopterin, a molecule, which augments immune
response during inflammation, was elevated in the circulatory
system of R428-treated rats (Fig. 4m). Both rat models exhibited
Fig. 1 Axl regulates the proliferation and migration of human pulmonary arterial smooth muscle cell (hPASMC). a, c HPASMCs from healthy individuals
and patients with idiopathic pulmonary arterial hypertension (IPAH) exposed to 30 ng/ml platelet-derived growth factor-BB (PDGF-BB) with or without
R428 at indicated concentrations. Control cells (co) were exposed to dimethyl sulfoxide (DMSO). Proliferation potential was assessed by 5-bromo-2′-
deoxyuridine (BrdU) colorimetric enzyme-linked immunosorbent assay (ELISA). Assessment of DNA synthesis was performed four hours after BrdU
addition [A370nm–A492nm]. Data from n= 4 biological independent experiments performed in triplicate are presented. b, d Migration efficiency was
determined by transwell migration assays. Data from n= 4 biological independent experiments performed in triplicate are presented as the n-fold change
normalized to DMSO-treated control cells. e, f Western blot images and densitometry quantification of Cyclin D1 and p27 expression in hPASMCs after
R428 treatment, followed PDGF-BB stimulation. Pan-actin served as a loading control. Data from n= 3 biological independent experiments are presented.
g, h Representative images and quantitative analyses of expression of proliferation marker Ki67 detected by immunofluorescence (green) in control
hPASMCs. DNA was visualized using 4′,6′-diamidino-2-phenylindole (DAPI; blue). Data from n= 4 biological independent experiments are presented.
Scale bar: 50 µm. i Real-time quantitative PCR analyses of AXL expression normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) house-
keeping gene in mRNA from hPASMCs after transduction with lentiviral constructs coding for Axl overexpression and Axl knock-down (short hairpin RNA),
compared with control-infected cells. Data from n= 4 biological independent experiments are presented. j, k Graph representing quantification of BrdU
incorporation in hPASMCs after PDGF-BB stimulation, pre-treated with increasing concentrations of R428, j after lentiviral overexpression of Axl and
control construct, and k after lentiviral transduction of Axl-silencing short hairpin RNA and control construct. Percentage of proliferated cells was
normalized to untreated control cells. Data from n= 2 biological independent experiments in triplicate are presented. Statistical analysis was performed
using one-way analysis of variance (ANOVA) with Tukey’s post hoc test for multiple comparisons. a–h **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus
DMSO-treated control cells; #P < 0.05, ##P < 0.01, ###P < 0.001, and ####P < 0.0001 versus PDGF-BB-treated cells. Open, green, and gray circles define
control (co), PDGF-BB-, and PDGF-BB+ R428-treated conditions, respectively. i ****P < 0.0001 versus control-infected (co and co sh) hPASMCs. All the
data are presented as mean ± SEM.
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an increase in the number of CD68 perivascular cells upon R428
administration (Supplementary Fig. 5e–h). R428 had a slight,
though not significant impact on suppressor of cytokine signaling
3 (SOCS3) expression (Fig. 4j and Supplementary Fig. 5a) and no
influence on p65 phosphorylation (Supplementary Fig. 5a, b).
Previous studies demonstrated that Axl inhibition induces an
adaptive immune resistance evidenced by unregulated pro-
grammed death ligand 1 (PD-L1) expression29. Interestingly,
expression of the immune checkpoint programmed death-1 (PD-
1)/programmed death ligand 1 (PD-L1) pathway, which plays a
key role in modulating immune response, was markedly induced
in experimental rat lungs (Supplementary Fig. 6a–e). R428
markedly enhanced the PD-1/PD-L1 axis compared with vehicle
in lungs from both rat models (Supplementary Fig. 6a–e), and
increased mRNA levels of C-X-C motif chemokine ligands
CXCL10 and CXCL11 (encoding chemokines associated with
type-1 T cell recruitment and functionality) (Supplementary
Fig. 6f, g). Taken together, our data indicate that Axl inhibition
augments both apoptotic and inflammatory responses in experi-
mental PAH.
R428 inhibits BMPR2 signaling in experimental PH. SuHOX
rats receiving R428 exhibited remarkable attenuation of the
BMPR2 signaling pathway, as determined by a decrease of
BMPR2 and inhibitor of DNA binding 1 (ID1) and ID2 on
mRNA, and BMPR2 and ID1 on protein levels compared with
control rats (Fig. 5a–f). Furthermore, R428 decreased circulating
E-selectin (a downstream target of BMPR2 in ECs) compared
with vehicle-treated control rats (Fig. 5d). A concomitant decline
Fig. 2 Axl inhibition suppresses the proliferation and induces the cytotoxicity and apoptosis of human pulmonary arterial endothelial cells (hPAECs). a
HPAECs from healthy individuals exposed to 10 ng/ml of epidermal growth factor (EGF) with or without R428 at indicated concentrations. Control cells
(co) were exposed to dimethyl sulfoxide (DMSO). Data from n= 3 biological independent experiments performed in triplicate are presented. Open, green,
and dark gray circles define untreated control (co), EGF, and EGF+ R428 conditions, respectively. b, c Cytotoxicity in donor and IPAH hPAECs was
determined by detecting lactate dehydrogenase (LDH) release into the cell culture media [A492nm–A620nm]. Cells treated with Staurosporine (SSP) were
used as a positive control. Data are reported as percentage release of LDH compared to DMSO-treated control (co) cells. Data from n= 3 biological
independent experiments performed in triplicates are presented as mean ± SEM. Number of d Hoechst and propidium iodide (PI) e positive hPAECs after
R428 treatment. Data from n= 4 (Hoechst) and n= 5 (PI) independent experiments presented as the n-fold change normalized to dimethyl sulfoxide
(DMSO)-treated control cells (co). f, g Relative mRNA expression of f intercellular adhesion molecule 1 (ICAM1) and g vascular cell adhesion molecule 1
(VCAM1) normalized to hypoxanthine guanine phosphoribosyl transferase (HPRT) as a reference gene after R428 treatment. Data from n= 3-5 biological
independent experiments are presented as the n-fold change (2−ΔΔCt) compared with DMSO-treated control (co). P values for distinct conditions are
given for their comparison with DMSO-treated control cells (co). Open and gray circles define DMSO- and R428-treated conditions, respectively. h
Analysis of AXL, ICAM1, and VCAM1 after small interfering RNA (siRNA) knock-down of AXL in hPAECs. AXL, ICAM1, and VCAM1 mRNA expression were
normalized to HPRT as a reference gene. Data from n= 3 biological independent experiments in triplicate are presented as the n-fold change (2−ΔΔCt)
compared with siRNA scrambled control (si co). Opened and black circles define si co and siAXL conditions, respectively. For statistical analysis in a–g one-
way ANOVA with Tukey’s post hoc test for multiple comparisons *P < 0.05, ***P < 0.001, and ****P < 0.0001 versus DMSO-treated control cells;
####P < 0.0001 versus EGF-treated cells were implemented; for h Student’s t-test *P < 0.05 and ***P < 0.001 versus scrambled siRNA control-transfected
cells. All the data are presented as mean ± SEM.
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in SMAD1/5/8 phosphorylation was observed in R428-treated
rats (Fig. 5e, f). The expression of phosphorylated SMAD2/3
proteins was markedly enhanced upon R428 treatment, indicating
that Axl inhibition on PAH is linked with a switch between TGF-
β-SMAD2/3 and BMPR2-SMAD1/5/8 signaling (Fig. 5e, f). In
SuHOX lungs, Axl protein correlated positively with BMPR2
abundance (Fig. 5g). Similarly, a highly significant correlation
between Axl and pSMAD1/5/8, but not pSMAD2/3 was found in
the lungs of the SuHOX rats (Fig. 5g). Outstandingly, western blot
analyses of lung protein extracts indicated that Axl inhibition
does not impact the expression of Activin A receptor type 2a
(ActR-2a) and Activin A receptor type 2B (ActR-2b) (Supple-
mentary Fig. 7a, b). These data indicate that Axl may contribute
to BMPR2 signaling.
R428 promotes vascular remodeling and pulmonary EC
apoptosis. We next examined whether Axl inhibition modulates
vascular remodeling in MCT and SuHOX treated rats. R428
increased neointima thickness of small pulmonary arteries in the
MCT rat model (Fig. 6a–c). Interestingly, R428 reduced the
neointima layer in the SuHOX model (Fig. 6f–h). Furthermore,
R428 increased the number of fully occluded vessels (Fig. 6d, i).
Vascular rarefaction is an important contributor to the hemo-
dynamic changes in patients with PAH30, which may occur by EC
apoptosis in distal arteries, evidenced by increased numbers of
circulating ECs31. Axl inhibition resulted in amelioration in total
number of small vessels in both rat models of experimental PAH
(Fig. 6e, j). R428 increased the percentage of apoptotic PAECs,
but not PASMCs in distal pulmonary arteries (Fig. 6k–n), and
declined the number of both pulmonary microvascular endo-
thelial cells (PMVECs) (Fig. 6o, p) and vWF-positive intra-
pulmonary ECs, compared with the vehicle (Fig. 6q). PCNA
immunostaining analyses reveal no remarkable effect on vascular
cell proliferation (Supplementary Fig. 7b–e).
Modulation of BMPR2 activity by Axl in hPAECs.
R428 significantly and dose-dependently reduced BMPR2 protein
in hPAECs (Fig. 7a, b) and BMPR2 transcripts in hPASMCs
Fig. 3 Axl inhibition aggravates hemodynamics, right ventricle (RV) hypertrophy, and RV function in monocrotaline (MCT) and Sugen 5416/hypoxia
(SuHOX) experimental rat models of pulmonary hypertension. a, f RV hypertrophy, measured as the ratio of RV to body weight (RV/BW). b, g Right
ventricular systolic pressure (RVSP, mmHg). c, h Cardiac output (CO, ml/min). d, i Tricuspid annular plane systolic excursion (TAPSE, mm). e, j Total
pulmonary vascular resistance index (TPVRI, mmHg/min/ml per 100 g body weight). a–e Echocardiography measurements were performed in male
Sprague-Dawley rats at baseline, 21 days after MCT administration, and again on day 35 after 2 weeks of daily treatment with R428 (100mg/kg body
weight). Hemodynamics and cardiac function were assessed on day 35 (MCT+ R428, n= 6; MCT+ placebo [MCT], n= 5; healthy, n= 6). f–j
Echocardiography measurements were performed in male Wistar-Kyoto rats at baseline, 21 days after Sugen 5416 administration and subsequent 3-week
hypoxic period, and on day 35 after 2 weeks of daily treatment with R428 (100mg/kg body weight) under normoxia. Hemodynamics and cardiac function
were assessed on day 35 (SuHOX+ R428, n= 9; SuHOX+ placebo [SuHOX], n= 8; normoxic rats [NOX], n= 8). Black circles NOX and Healthy controls;
blue squares MCT and SUHOX, and red triangles MCT+ R428 and SuHOX+ R428. All statistical analyses were performed using one-way ANOVA with
Tukey’s post hoc test for multiple comparisons. *P < 0.05, **P < 0.01, and ****P < 0.0001 for placebo-treated rats versus respective controls; #P < 0.05,
##P < 0.01, and ###P < 0.001 for R428-treated rats versus placebo-treated controls. All the data are presented as mean ± SEM.
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02531-1 ARTICLE
COMMUNICATIONS BIOLOGY |          (2021) 4:1002 | https://doi.org/10.1038/s42003-021-02531-1 | www.nature.com/commsbio 5
(Supplementary Fig. 8a). In hPAECs, the decline of BMPR2 was
associated with a decrease in mRNA levels of its downstream
target, E-selectin (Fig. 7c), indicating that Axl may contribute to
BMP responsiveness in hPAECs. BMP signaling is majorly con-
trolled by BMP2, 4, 6, 9, and 10 factors in vascular endothelium32.
Axl phosphorylation was found to occur upon short-term sti-
mulation with all studied BMPs except BMP2 (Fig. 7d), indicating
a selective involvement of distinct BMPs in Axl activation. Of the
studied BMPs, BMP9 has been shown previously to promote
PAEC survival33 and protect PMVECs from apoptosis34. We
therefore investigated the effect of BMP9 on Axl cascade
activation. Short-term BMP9 stimulation resulted in a significant
and time-dependent phosphorylation of Axl (Fig. 7e), while Gas6
enhanced the activation of BMPR2 signaling via phosphorylation
of SMAD1/5/8 and ID1 increase (Fig. 7f–h and Fig. 8a, b).
Importantly, Gas6 neutralizing antibody completely obstructed
Gas6-mediated SMAD1/5/8 activation (Supplementary Fig. 8b)
and BMPR2 increase (Supplementary Fig. 8c). Inhibition of BMP
signaling by LDN-193189 diminished the Gas6-induced phos-
phorylation of SMAD1/5/8 and ID1/ID2 increase (Fig. 7g, h).
Both ligands protected hPAECs from R428-induced apoptosis
(Fig. 7i, j). Moreover, Axl blockage by R428 significantly inhibited
Fig. 4 Effect of R428 on apoptotic, inflammatory, and immune responses in the Sugen 5416/hypoxia (SuHOX) experimental rat model of pulmonary
hypertension. a Representative western blots of markers of apoptosis. b Subsequent densitometric quantification of Cleaved Caspase. c Quantitative
analyses of Caspase-positive cells per vessel. d, e Densitometric quantification of d p53 and e p21. f, g, m Enzyme-linked immunosorbent assay (ELISA) for
analysis of the presence of phosphatidylserine (Ptd-L-Ser), anti-cardiolipin antibody IgG (ACA-IgG) and neopterin in plasma of rats. h–j Densitometric
quantification of markers of inflammation h nitrotyrosine, i phosphorylated signal transducer and activator of transcription 3 [phospho-STAT3], and j
suppressor of cytokine signaling 3 [SOCS3]) in total lung homogenates. k, l Real-time quantitative PCR analysis of k interferon γ (Ifn-γ) and l interleukin 6
(Il-6) mRNA expression in lungs of rats. Data are presented as the n-fold change (2−ΔΔCt) normalized to hypoxanthine guanine phosphoribosyl transferase
(Hprt) as a reference gene, compared with NOX. The numbers of biological independent rats included in the analyses were as follows. Western blots and
densitometric quantification: normoxic rats (NOX), n= 4; SuHOX+ placebo (SuHOX), n= 5; SuHOX+ R428, n= 5. Real-time quantitative PCR: NOX,
n= 5; SuHOX, n= 6; SuHOX+ R428, n= 7. ELISAs: NOX, n= 4–6; SuHOX, n= 6; SuHOX+ R428, n= 6–9. Black circles NOX controls; blue squares
SUHOX; red triangles SuHOX+ R428. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test for multiple comparisons.
*P < 0.05 and **P < 0.01 versus NOX; #P < 0.05, ##P < 0.01, and ####P < 0.0001 for SuHOX+ R428 versus SuHOX. All the data represent the mean ± SEM.
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BMP9-induced BMP signaling at the expense of ID1 protein
decrease (Fig. 8a, b). The knock-down of Axl and BMPR2 each
diminished both BMP9- and Gas6-induced SMAD1/5/8 activa-
tion directly and reciprocally (Fig. 8c, d).
A significant reduction of ID1, and ID2 mRNA transcripts was
also noted in Axl small interfering RNA-treated hPAECs,
indicating that Axl is required for BMP signaling transduction
to Smad1/5/8 phosphorylation and ID1/ID2 increase in ECs
(Fig. 8e). Similarly, BMPR2 knock-down lessened Gas6-prompted
augmentation of ID1/ID2 expression, suggesting an interaction of
both pathways.
Axl is physically associated with BMPR2. Next, we looked at the
expression of Axl receptor in clinical PAH. Interestingly, despite
an elevation of Axl expression in lung homogenates of clinical
PAH (Supplementary Fig. 8d), no changes in the expression
profile of Axl protein were found in hPASMCs isolated from non-
PAH individuals and IPAH patients (Supplementary Fig. 8e).
Outstandingly, Axl demonstrates a highly significant positive
correlation with BMPR2 abundance in hPASMCs (Supplemen-
tary Fig. 8g). Concomitantly, a substantial decline in AXL mRNA
in MDVs of patients with IPAH compared with non-PAH
controls was determined (Fig. 9a). Similarly, BOECs isolated from
patients with IPAH exhibited a tendency of reduced AXL
expression (Fig. 9b). Moreover, hPAECs from IPAH patients
exhibited a decline of Axl protein in comparison to non-PAH
control PAECs (Fig. 9c, d). A robust correlation between Axl and
BMPR2 protein expression in hPAECs was found (Fig. 9e). A
decay of Axl protein in cultured hPAECs was corresponding to its
drop in pulmonary endothelium in lung specimens of patients
with IPAH, as revealed by immunofluorescence staining with von
Willebrand factor (vWF) and α-smooth muscle actin (α-SMA)
antibodies (Fig. 9f and Supplementary Fig. 8h). In HEK293 cells,
overexpressed Axl co-immunoprecipitated with overexpressed
BMPR2 and vice versa (Fig. 9g, h). In hPAECs, endogenous
BMPR2 co-immunoprecipitated with endogenous Axl, indicating
that Axl is a novel interacting partner of BMPR2 (Fig. 9i). Both
immunoprecipitations and proximity ligation assays exhibited
enhanced receptor–receptor interaction after simultaneous
BMP9/Gas6 stimulations of hPAECs (Fig. 9j–l). R428 efficiently
blocked receptor–receptor interaction under basal and stimulated
conditions (Fig. 9k, l). Taken together out data point to a pre-
viously unrecognized association between RTK Axl and BMPR2
in PAECs.
Fig. 5 Effect of R428 on BMPR2 signaling pathway in the Sugen 5416/hypoxia (SuHOX) experimental rat model of pulmonary hypertension. a–c Real-
time quantitative PCR analysis of bone morphogenetic protein receptor 2 (BMPR2) and inhibitor of DNA binding 1 (ID1) and 2 (ID2) mRNA expression. Data
are presented as the n-fold change (2−ΔΔCt) normalized to hypoxanthine guanine phosphoribosyl transferase (Hprt) as a reference gene, compared with
normoxic control rats (normoxic [NOX], n= 5; SuHOX+ placebo [SuHOX], n= 6; SuHOX+ R428, n= 7 biological independent animals). d Enzyme-
linked immunosorbent assays for analysis of the presence of E-selectin in plasma of biological independent rats (NOX, n= 8; SuHOX, n= 7;
SuHOX+ R428, n= 9 biological independent animals). e Western blots and f subsequent densitometric quantification of BMPR2, Axl, phospho-SMAD1/
5/8, phospho-SMAD2, phospho-SMAD3, and ID1 expression in lung homogenates of representative samples from all three studied groups (NOX, n= 4;
SuHOX, n= 4-5; SuHOX+ R428, n= 4–5 biological independent animals). Vinculin and Pan-actin served as a loading controls. g Analyses of the
correlation between BMPR2, pSMAD1/5/8, pSMAD2, pSMAD3, and Axl expression in total lungs of rats from SuHOX experimental model. Pearson
correlation coefficient (r value) and the significance (two-tailed P value) of each correlation analysis are represented. Black circles NOX controls; blue
squares SUHOX; red triangles SuHOX+ R428. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test for multiple
comparisons. *P < 0.05, **P < 0.01, and ***P < 0.001 for SuHOX versus NOX; #P < 0.05, ##P < 0.01, ###P < 0.001, and ####P < 0.0001 for SuHOX+ R428
versus SuHOX. All the data represent the mean ± SEM.
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Discussion
To the best of our knowledge our study is the first investigation of
the role of the Gas6/Axl pathway in PH. We found an altered Axl
expression in experimental PH and patients with IPAH and
showed that Axl inhibition by R428 worsened experimental PH
and augmented hPAEC apoptosis. Both MCT and SuHOX ani-
mal models have been employed for decades to develop experi-
mental PAH, by inducing both PH and RVH. MCT, a highly
toxic alkaloid, when ingested stimulates widespread pneumo-
toxicity, connected with increased cell proliferation and systemic
inflammation35. In SuHOX model, SU5416-mediated VEGFR2
blockade, in combination with hypobaric hypoxia, induces a
severe PH with elements of inflammation and angio-
obliteration36. Both models are characterized by EC injury that
also have been associated with BMPR2 dysregulation and BMP
signaling deficiency. In contrast to SuHOX model of severe PAH,
MCT model does not exhibit EC-mediated angio-obliteration, but
reveals pronounced pulmonary arterial hypertrophy35. In our
study, Axl blockage of MCT-administered rats resulted in a sig-
nificant increase in neointima/media ratio, suggesting that EC
dysfunction in this model is a direct consequence of EC damage.
These data are consistent with previously published results in
which Axl activation rescued human umbilical vein ECs and
hPAECs from apoptosis37–39, and systemic deletion of Axl in
mice increased apoptosis in vein graft remodeling40. Moreover,
the Gas6/Axl pathway has been shown to contribute to high-
glucose-induced EC dysfunction41, suggesting that Gas6-
dependent signaling may be relevant to EC survival in the
quiescent environment of the vessel wall. Interestingly, while Axl
expression is markedly induced in whole-lung tissue samples of
Fig. 6 Axl blockage by R428 administration exacerbates lung tissue remodeling in monocrotaline (MCT) and Sugen 5416/hypoxia (SuHOX)
experimental rat models of pulmonary hypertension. a, f Representative images of immunohistological staining of lung sections for von Willebrand factor
(vWF; brown) and α-smooth muscle actin (α-SMA; violet) in a monocrotaline (MCT) and f Sugen 5416/hypoxia (SuHOX) models of pulmonary
hypertension. Scale bar: 20 µm. b, g The neointima thickness (µm) and c, h the neointima/media of the studied groups determined by Elastica-van-Gieson
staining in the vessels with a diameter of 20–50 µm. d, i Number of occluded vessels with a diameter of 20–50 µm (per 100 vessels). e, j Number of vessels
counted per lung (normalized per surface area) a–i MCT model: healthy, n= 5–6; MCT+ placebo [MCT], n= 5; MCT+ R428, n= 6. SuHOX model: NOX,
n= 7; SuHOX+ placebo [SuHOX], n= 7–8; SuHOX+ R428, n= 7–8 biological independent animals. Data are presented as mean ± SEM of all counted
vessels per lung. k, l Representative images and m, n quantification of TUNEL-positive cells in lungs of SuHOX rats and controls (k α-SMA [green] and l
vWF [green]; nuclei, blue (diamidino-2-phenylindole [DAPI]). Graphs represent the percentage of PASMCs and PAECs positive for TUNEL in distal
pulmonary vessels of lung rats. o Representative images and p quantitative analysis of immunofluorescent staining of lung sections for pulmonary
microvascular endothelial cells (PMVECs) using isolectin IB4 (red). Scale bar= 50 µm. q Quantitative analysis of immunofluorescent staining of lung
sections for pulmonary endothelial cells (PAECs) using vWF antibody. m–q NOX, n= 7; SuHOX+ placebo [SuHOX], n= 7; SuHOX+ R428, n= 7
biological independent animals. b–d *P < 0.05, **P < 0.01 for MCT (or MCT+ R428) versus healthy; g–i ****P < 0.0001 for SuHOX (or SuHOX+ R428)
versus NOX; c–j #P < 0.05, ##P < 0.001, and ####P < 0.001 for MCT+ R428 and SuHOX+ R428 versus MCT or SuHOX, respectively. Black circles NOX
controls; blue squares SUHOX; red triangles SuHOX+ R428. b–q Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc test
for multiple comparisons. e, j Student’s t-test was applied. All the data represent the mean ± SEM.
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IPAH patients, in comparison to non-PAH control individuals,
no difference of the Axl expression in hPASMCs from IPAH
patients versus non-PAH control cells was noted. In contrast, the
expression of Axl was strongly induced in rat and mouse PH-
PASMCs. Outstandingly, Axl receptor was prominently reduced
both in the pulmonary endothelium and isolated hPAECs of
patients with IPAH, indicating a selective and EC-specific mode
of regulation. We found a cross-talk between the Gas6/Axl and
BMP9/BMPR2 signaling pathways and identified a previously
unrecognized physical association between Axl and BMPR2.
Interactions of Axl with other receptors of TAM and non-TAM
families have been implicated in various functional outcomes.
The association of Axl and integrin complexes has been postu-
lated to contribute to Axl-mediated anti-apoptotic effects induced
by laminar shear stress in ECs14, while the interaction of Axl with
HER2 at the cell surface is required for invasion and metastasis in
HER2-positive breast cancer42. Axl is present in local clusters
together with ErbB and MET receptors on the plasma membrane
of cancer cells11. Such clustering of plasma membrane receptors
results in activation-dependent enhancement of interactions after
ligand stimulation43. In our experiments, an interaction between
Axl and BMPR2 was facilitated by concomitant ligand stimula-
tion, signifying receptor clustering at the plasma membrane of
ECs. This association was weakened by the addition of R428 in
hPAECs. BMPR2 presence in pulmonary arteries is a critical
determinant of PAH, as patients with IPAH without a BMPR2
mutation or with PAH associated with other related medical
conditions exhibit a decay in the expression of BMPR2 in
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pulmonary arteries44. The interaction of Axl with BMPR2 at the
cell surface of PAECs might be required for maintaining the local
clusters between receptors and thereby EC homeostasis, while the
inhibition of Axl signaling might trigger EC apoptosis, eventually
enhancing dysfunctional BMPR2 signaling in the context of PAH.
Like the others, we did not detect the changes of BMPR2 and its
downstream signaling component phopsho-Smad1/5/8 in the
whole-lung lysates of rats of SuHOX model45, however Axl
inhibition triggered the decline of BMPR2 signaling both on the
level of BMPR2 and phospho-Smad1/5/8 proteins, as well as EC-
specific downstream target of BMPR2, E-selectin, confirming the
detrimental impact of Axl inhibition in the context of PAH. Like-
wise, the inhibition of Axl in cultured hPAECs significantly
inhibited BMPR2 signaling at the expense of decrease of Smad1/5/8
phosphorylation and ID1, ID2, and E-selectin expression, verifying
that Axl is required for BMPR2 signaling in ECs. Interestingly,
Gas6-mediated Axl activation enhanced BMPR2 signaling and
protects from R428-induced hPAEC apoptosis, while inhibition of
BMPR2 signaling by LDN-193189 diminished the Gas6-induced
phosphorylation of SMAD1/5/8 and ID1 increase, suggesting that
Gas6/Axl might play a protective role in the pulmonary endothe-
lium in the context of PAH.
Loss of precapillary vessels and impaired vascular regeneration
are two sides of vessel remodeling in PAH46. Gas6 (via Axl
activation) may, similarly to BMP447 and BMP933, enhance
PAEC survival and potentially increase tube formation, both
essential for the recovery of remodeled vessels in PAH. Further-
more, Axl blockage may prolong the initial period of EC pre-
disposition to apoptosis in SuHOX rats, which markedly affects a
secondary hyper-proliferative EC phenotype culminating in PH.
In this regard, the sustained levels of Axl phosphorylation may
serve as an essential prerequisite for EC survival in PAH.
Importantly, BMP9-induced Axl phosphorylation, confirms the
protective role of Axl phosphorylation in cultured hPAECs.
TAM RTKs have been shown to reduce JAK/STAT-mediated
immune responses21,48, while TAM triple knock-out activates the
production of inflammatory cytokines49. Blockage of Axl in our
disease settings induced pro-inflammatory signaling, consistent
with a recent study in which R428 antagonized the anti-
inflammatory effect of Gas6 in ischemia reperfusion-induced
acute lung injury, suggesting that Gas6-induced Axl phosphor-
ylation is protective not only in alveolar epithelium50, but also in
the vascular endothelium.
Recently, Axl was demonstrated to be unsusceptible to com-
bined irradiation and PD-L1 immunotherapy, while Axl knock-
down contributed to reprogramming of the immunological
microenvironment, suggesting that disabling Axl signaling may
promote adaptive immunity51,52. The binding of PD-L1 to PD-1
transmits an inhibitory signal suppressing adaptive immune
responses. As expected, Axl inhibition in our experimental
models of PH strongly activated PD-1/PD-L1 signaling, indicat-
ing downregulation of the adaptive immune system. It was pre-
viously postulated that antibodies against the vascular
endothelium might promote endothelial apoptosis, which might
serve as a hallmark of autoimmune disorders53. Moreover, Axl
inhibition was shown to upregulate neopterin, a marker of PAH
and inoperable chronic thromboembolic PH54 which can be
released by both inflammatory cells and ECs55. In R428-treated
rats, the neopterin increase was accompanied by a remarkable
upregulation of anti-phospholipid antibodies that bind and acti-
vate ECs, resulting in their apoptosis56,57. Furthermore, Axl
inhibition enhanced cardiolipin antibody, a molecule essential for
the recruitment of apoptotic factors and inflammasome
formation58. Thus, we assume that Axl inhibition results in
autoantibody production and associated vascular endothelial
injury, which contributes, in combination with other genetic and
environmental factors, to the emergence of PAH. Gas6/Axl sig-
naling plays an important role in phagocytosis, suppression of the
inflammatory cytokine response, and final resolution of anti-
inflammatory processes4,59–61, thus it is not surprising that
ablation of Axl signaling resulted in the overproduction of pro-
inflammatory cytokines/chemokines in our disease setting.
Recent studies indicate that apoptotic cells can be involved in
autoimmune processes53,62. Thus, it is conceivable that endo-
thelial apoptosis and autoimmune injury may also occur sec-
ondary to R428-dependent BMPR2 decline. Interestingly, TAM
family receptors heterodimerize with each other and with other
RTKs, which often serve as an essential mode of their activation.
An interaction of BMPR2 with VEGFR3 has been recently
described in ECs63. Impairment of BMP signaling and exacer-
bation of hypoxia-induced PH has been determined in
endothelial-specific VEGFR3 knock-out mice, proposing a novel
mechanism of BMPR2 modulation in the context of PAH63. To
the best of our knowledge, this is the first study demonstrating
Axl as a key regulator of endothelial BMPR2 signaling and
potential determinant of PAH emergence in humans. Our results
demonstrate that although Axl can function as an oncogene in
various cancers, it plays protective role against PAH development:
(1) by halting the disease progression upholding the intrinsic
mechanisms of EC survival; (2) by maintaining the BMP
Fig. 7 Mutually mediated interaction of bone morphogenetic receptor 2 (BMPR2) and Axl signaling pathways in human pulmonary arterial endothelial
cells (hPAECs). a Western blots and b subsequent densitometry quantification of BMPR2 and phospho-Axl in hPAECs exposed to R428 at the indicated
concentrations. Opened triangles and dark gray circles denote BMPR2 and pAxl, respectively. c Relative mRNA expression of E-selectin normalized to
hypoxanthine guanine phosphoribosyl transferase (HPRT) as a reference gene. Data from n= 4 biological independent experiments are presented as the n-
fold change (2−ΔΔCt) compared with DMSO-treated control cells. d Endogenous levels of tyrosine-phosphorylated Axl analyzed by PathScan® phospho-Axl
(panTyr) Sandwich ELISA. c, d Opened circles define untreated control (co) cells, light gray circles define R428, dark gray circles define BMP2-10 and Gas6
conditions. e, f Western blots of e Axl, and f SMAD1/5/8 phosphorylation after BMP9 (10 ng/ml) and Gas6 (200mg/ml) stimulation. g Western blots and
subsequent densitometry quantification of SMAD1/5/8 phosphorylation after LDN-193189 (2.5 µM) treatment followed by Gas6 and BMP9 stimulations
(30min). h Relative mRNA expression of inhibitor of DNA binding 1 and 2 (ID1, ID2) normalized to HPRT as a reference gene. Data from n= 4 biological
independent experiments are presented as the n-fold change (2−ΔΔCt) compared with control-treated control cells. g, h Untreated control (co) is defined
with opened circles. Green, purple and black circles define Gas6-, BMP9-, and LDN19189-treated conditions, respectively. i, j Western blots and subsequent
densitometry quantification of Cleaved Caspase and Bcl2 after R428 treatment followed by Gas6 or BMP9 (24 h). b, d, g–j Data from n= 3 biological
independent experiments are presented as the n-fold change compared with b, i, j DMSO-treated or d, g, h untreated control (co) cells. Untreated control
(co) is defined with opened circles. Black, light gray, and dark circles define R428-, R428+ BMP9-, and R428+Gas6-treated conditions, respectively.
Statistical analyses were performed using one-way ANOVA with Tukey’s or Newman-Keuls post hoc test for multiple comparisons. a–j *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 versus untreated or DMSO-treated control cells; g, h ##P < 0.01, ###P < 0.001, and ####P < 0.0001 for LDN-193189 versus BMP
and Gas6 stimulations, and i, j #P < 0.05, ##P < 0.01, and ####P < 0.0001 R428+ BMP9 and R428+Gas6 versus R428. In a, e, g Pan-actin, in f, i Vinculin
served as a loading control. All the data represent the mean ± SEM.
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Fig. 8 Modulation of bone morphogenetic receptor 2 (BMPR2) signaling pathway by Axl in human pulmonary arterial endothelial cells (hPAECs). a, b
Western blots and subsequent densitometry quantification of phospho-Axl, BMPR2, and ID1 after R428 treatment followed by Gas6 or BMP9 (2 h). Data
from n= 3 biological independent experiments are presented as the n-fold change compared with DMSO-treated control (co) cells, defined with opened
circles. Green and purple circles define Gas6 and BMP9. Light gray and dark gray circles define R428+ BMP9- and R428+Gas6-treated conditions,
respectively. c, d Representative western blots of Axl, BMPR2, and pSMAD1/5/8 and quantitative analyses of pSMAD1/5/8 expression upon the small
interfering RNA (siRNA) treatment of Axl and BMPR2 in hPAECs. Opened circles define si scrambled (si co) cells, green and purple circles define BMP9
and Gas6 cells, respectively. Light gray and dark gray circles define siAxl and siBMPR2 cells, respectively. Data from n= 3 biological independent
experiments are presented as the n-fold change compared with untreated control (co) cells. e Quantitative real-time PCR analyses of ID1 and ID2 after
siRNA-mediated knock-down of Axl and BMPR2 and followed by BMP9 and Gas6 stimulations. Data from n= 3 biological independent experiments are
presented as the n-fold change (2−ΔΔCt) compared with scrambled siRNA control (si co). Statistical analyses were performed using one-way ANOVA with
Tukey’s or Newman-Keuls post hoc test for multiple comparisons. a–e ***P < 0.001, ****P < 0.0001 versus untreated scrambled siRNA controls (si co) or
DMSO-treated control (co) cells; a, b #P < 0.05, ##P < 0.01 R428+ BMP9 and R428+Gas6 versus R428; c–e #P < 0.05, ##P < 0.01, ###P < 0.001,
####P < 0.0001 for si co+ BMP9, si co+Gas6 versus si Axl+Gas6/BMP9, and siBMPR2+ BMP9/Gas6. In a Pan-actin, in c Vinculin served as a loading
control. All the data represent the mean ± SEM.
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Fig. 9 Axl closely associates with bone morphogenetic protein receptor 2 (BMPR2). a Real-time quantitative PCR analyses of AXL mRNA expression
normalized to 18S in laser-assisted microdissected vessels (MDVs) from non-PAH biological independent controls (n= 7) and patients with IPAH (n= 10).
b Real-time quantitative PCR analyses of AXL expression in mRNA from BOECs of non-PAH biological independent controls (n= 3) and patients with IPAH
(n= 7), normalized to β2-microglobulin (B2M). c Western blot analysis and d subsequent densitometric quantification of Axl expression in human
pulmonary arterial endothelial cells (hPAECs), isolated from biological independent patients with IPAH (n= 5) and non-PAH controls (n= 4). Pan-actin
served as a loading control. e Analysis of the correlation between BMPR2 and Axl expression in hPAECs from patients with IPAH (n= 5) and non-PAH
(n= 4) controls. Pearson correlation coefficient (r value) and the significance (P value) of correlation analysis is represented on the graph. **P < 0.01,
*P < 0.5 versus non-PAH control (co). For statistical analyses Student’s t-test and correlation analyses were applied. f Representative examples of
immunofluorescence staining of Axl (green) expression in tissue sections of non-PAH (n= 4) and IPAH (n= 4) human lung specimens. Sections were
double stained with von Willebrand factor (vWF) (red) antibody. White arrowheads depict the expression of Axl in PAECs. Nuclei were visualized using
4′,6′-diamidino-2-phenylindole (DAPI; blue). Scale bars: 50 µm. g, h In HEK293 cells overexpressing Flag-Axl and BMPR2-Myc, g co-immunoprecipitation
using Flag antibody to target Axl protein pulled down BMPR2 protein, and h co-immunoprecipitation using BMPR2 antibody pulled down Axl protein.
Representative pictures of three independent experiments are shown. i Co-immunoprecipitation using BMPR2 antibody pulled down endogenous Axl in
hPAECs j co-immunoprecipitations after 48 h of hPAEC stimulation with BMP9/Gas6. WCL=whole-cell lysate; IP= immunoprecipitant. k Representative
immunofluorescent images and l quantification of interaction between BMPR2 and Axl by Proximity Ligation (PLA) assay in hPAECs treated with R428
followed by BMP9/Gas6 stimulation. PLA shows close proximity of Axl and BMPR2 in hPAECs. Duolink Axl/BMPR2= PLA fluorescence signal; Duolink
Axl/BMPR2/DAPI=merged PLA/diamidino-2-phenylindole fluorescence signals. Scale bars: 50 μm. Images are representative of four independent
experiments. Statistical analyses were performed using one-way ANOVA with Newman-Keuls post hoc test for multiple comparisons. **P < 0.01 and
##P < 0.001 versus DMSO-treated control (co) cells; $$$$P < 0.0001 versus BMP9/Gas6 stimulation. All the data represent the mean ± SEM.
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signaling in PAECs; and (3) by controlling the inflammation.
Thus, Axl-mediated aggravation of PAH might be partly
explained by proliferative/proinflammatory reprogramming of
vascular wall cells, driven by BMPR2-related EC apoptosis
(Fig. 10). Together, our results indicate that the systemic targeting
of Axl in the context of PAH involves a number of potential
pitfalls and may increase the risk of PH.
Methods
Human biomaterial. Primary human PASMCs from healthy individuals were
obtained either from Lonza (CC-2581 Basel, Switzerland) or from the UGMLC
Giessen Biobank of the Justus-Liebig University Giessen (Giessen, Germany).
HPASMCs from patients with PAH were obtained exclusively from the UGMLC
Giessen Biobank. The human biomaterial collection was approved by the Ethics
Committee of the Justus-Liebig University (ethics vote number 58/15). The patients
have been informed and given their written consent for the use of biomaterials for
research purposes. Human PASMCs were maintained in Smooth Muscle Cell
Growth Medium-2 (SMC GM-2) (Lonza, CC-3182, Basel, Switzerland), provided
with supplement mix, containing 5% fetal bovine serum (FBS), human basic
fibroblast growth factor (hFGF-B, 2 ng/ml), epidermal growth factor (hEGF, 0.5 ng/
ml), and insulin (5 µg/ml). hPAECs from healthy individuals were purchased from
PromoCell (C-12241, Heidelberg, Germany). The human lung specimens used for
PAH-hPAEC cultures were obtained from patients with PAH during lung trans-
plantation. PAH was diagnosed by cardiac catheterization at the National Refer-
ence Center for PAH, in a program approved by our institutional ethics committee,
Comité de Protection des Personnes Ile-de-France VII, and written informed
consent for participation in the study was obtained (protocol N8CO-08- 003, ID
RCB:2008-A00485-50). Lung histology was assessed by a pathologist, after trans-
plantation, and confirmed the diagnosis of PAH. PH was defined as resting mean
pulmonary arterial pressure ≥25 mmHg. Human PAECs were maintained in cul-
ture with Endothelial Cell Growth Medium 2 (EGM-2), consisting of 2% FBS, 5 ng/
ml hEGF, 10 ng/ml hFGF-B, 20 ng/ml R3 IGF-1, 0.5 ng/ml VEGF, 1 µg/ml ascorbic
acid, 22.5 µg/ml heparin, and 0.2 µg/ml hydrocortisone (PromoCell GmbH, C-
22111, Heidelberg, Germany). Cells were maintained in complete EC growth
medium-2 (EGM-2) and were used at passages 4–6. Blood outgrowth ECs (BOECs)
were obtained and cultured as described previously64,65. All studies and procedures
to obtain human specimens were directed according to the Declaration of Helsinki.
Both platelet-derived growth factor (PDGF-BB) and growth medium (GM), a
mixture of growth factors were applied, as PAH stimuli for proliferation assays. For
stimulation experiments, hPASMCs were starved in serum-free SMC Basal
Medium (without supplement mix) for 24 h before each experiment and then
treated with R428, as indicated. For the stimulation experiments hPAECs were
starved for 20 h before each experiment in the medium M200 (M200500, Thermo
Fisher Scientific, Waltham, USA) with addition of 2% FBS (AC-SM-0033,
Anprotec, Bruckberg, Germany). Cells were exposed to R428 /BGB324 (HY-15150,
MedChem Express, Monmouth Junction, USA) at the concentrations indicated in
the figures. After one hour of R428 treatment, human PASMCs and PAECs were
stimulated with recombinant PDGF-BB (30 ng/ml), SMC GM-2, Gas6 (200 ng/ml),
or various BMPs (all at 10 ng/ml) either for 24 h, 48 h, or as indicated in the figures.
For the determination of tyrosine phosphorylation of Axl by PathScan Phospho-
Axl (panTyr) Sandwich ELISA assay, hPAECs were grown for 24 h, starved for 20 h
and then stimulated with bone morphogenetic proteins (BMPs; all at 10 ng/ml) and
growth arrest-specific protein 6 (Gas6; 200 mg/ml) for 2 h. All experiments were
performed with cells between passages 5 and 7. Visual analysis was carried out by
bright-field microscopy (Eclipse TS100; Nikon GmbH, Duesseldorf, Germany).
Proliferation and migration assays. Proliferation of human PASMCs was
determined by measuring the incorporation of 5-bromo-2′-deoxyuridine (BrdU)
with a colorimetric cell proliferation enzyme-linked immunosorbent assay (Cell
Proliferation ELISA, BrdU kit) and by immunofluorescent analyses of the
expression of proliferation marker Ki67 (ACK02, Leica, Wetzlar, Germany).
Quantification of DNA synthesis by a colorimetric BrdU ELISA was carried out by
absorbance measurement at 370 nm using 492 nm as a reference wavelength, and
final graphs represent data from four individual experiments performed in tripli-
cates. For analyses of Ki67 staining, 150–200 human PASMCs in five random fields
of two different subpopulations were counted in each experiment. Proximity
Ligation Assays (PLA) have been performed according to manufacturer’s
instructions (Duolink® Proximity Ligation kit, Merck, Darmstadt, Germany).
Two types of the migration experiments have been performed: the wound-
healing assays and the transwell assays. The predefined wound areas for the
wound-healing assays were created by removable cell culture inserts (Ibidi,
Planegg/Martinsried, Germany). The wound areas were photographed before and
after 16 h of incubation with PDGF-BB (30 ng/ml) with or without R428. The
images were taken using a Leica inverted microscope (Leica, Wetzlar, Germany).
The absence of proliferation was ensured by the addition of cytosine arabinoside
(AraC). At 16 h after the completion of experiments, hPASMCs were fixed and
stained with DAPI (4′,6′-diamidino-2-phenylindole, 0.5 μg/ml, Sigma, Munich,
Germany). Migration rate was measured by quantifying the number of DAPI-
positive hPASMCs that were migrated into the wound region. Results are given at
an n-fold change normalized to the absorbance for DMSO-treated control cells
after 24 h. The Infinite M200 Pro instrument from Tecan Group (Männedorf,
Switzerland) was used to determine the absorbance at the desired wavelengths.
Cloning of LeGO vectors and production of lentiviral particles. Cloning of
LeGO vector for overexpression of human Axl was performed based on the Len-
tiviral gene ontology overexpression system (for detailed protocols and vector maps
refer to http://www.lentigo-vectors.de). Full-length cDNA clone for Axl
(pDONR223, #23945) was purchased from Addgene (Cambridge MA, USA). For
overexpression, full-length cDNA from this vector was cloned into the LeGO-iG2-
Puro+ vector using EcoRI and NotI restriction enzymes (New England Biolabs)
according to standard protocols. Primers and probes were purchased from Applied
Biosystems (https://products.appliedbiosystems.com). Sequences of primers used
for cloning are as follows, forward primer: 5′-atatgaattccgccaccatggcgtggcggtgcc-3′,
and reverse primer: 5′-atatgcggccgcctaggcaccatcctcctgcc-3′. For silencing Axl
pLKO.1 vector containing shRNA Axl sequence 5′-ccggcgaaatcctctatgtcaa-
catctcgagatgttgacatagaggatttcgttttt-3′ was purchased from Sigma MISSION. The
complete sequence of shRNA Axl, including the U6 promoter, was cloned in a
LeGO-Cer-BSD vector. PspOMI and XhoI (New England Biolabs) enzymes were
used for these steps. Sequences of primers used for PCR amplification to enrich
sequence from pLKO.1 vector are as follows, forward primer: 5′-acggtatcgatcac-
gagactagcctcgagc-3′ and reverse primer: 5′-tactgccatttgtgtcgacgtcgagaattc-3′. PCR-
amplified fragments of new vectors were verified by DNA sequencing. Over-
expression Axl was confirmed by qPCR. Primers used for PCR amplification are
described by the following assay IDs, human GAPDH (Hs99999905_m1) and
Fig. 10 Proposed model of the effect of R428 on bone morphogenetic protein receptor (BMPR) 2 signaling and multiple facets of the inhibition of
Gas6/Axl signaling in PAH. a BMP signaling and EC homeostasis are maintained by Axl signaling. Gas6/Axl guards the anti-inflammatory response, EC
survival and homeostasis by augmentation of BMPR2-related canonical SMAD. b The inhibition of Axl by R428 leads to the inhibition of canonical BMP/
SMAD signaling, augmentation of inflammation, adaptive immune evasion, EC apoptosis and microvascular rarefaction. ID1= inhibitor of DNA binding 1;
SMAD=mothers against decapentaplegic homolog 7; EC= endothelial cell; Gas6= growth arrest-specific 6; IL6= Interleukin 6; IFN-γ- Interferon gamma;
ICAM1= Intercellular Adhesion Molecule 1; PD-1/PD-L1= programmed death ligand-1/programmed cell death-1.
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human Axl (Hs01064444_m1). Only cells with 4-fold overexpression compared to
control transduced cells were used for experiments. After transduction of PASMC
cells with fluorochrome-marked lentiviruses mediating Axl overexpression, cells
were exposed to R428 treatments and cultured in standard conditions
Transfection with Axl siRNA. Human PAECs were transfected with siRNA
against Axl using the SMARTpool: ON-TARGETplus AXL siRNA (10 nmol) (L-
003104-00-0010), using the ON-TARGETplus Non-targeting Control Pool (D-
001810-10-20). Shortly, the transfection was performed using the Dharma-
FECT1TM (DharmaFECT1, GE Dharmacon). The siRNA/ DharmaFECT1TM
complexes were diluted in the ratio of 9 μl per 6 cm dish in Opti-MEM I medium
(Fa. Gibco, 31985-047). After 4 h of incubation, the medium was replaced by EGM-
2 and the cells were kept for additional 20 h. The starvation prior to the stimulation
was performed in M200 medium for 20 h, and then the cells were treated with
BMP9 for the times described in the figure legends. The knock-down of the rele-
vant RNA transcripts and protein were quantified using qPCR and western blotting
analyses, respectively.
Plasmids, transfection of HEK293 cells, and immunoprecipitations. HEK293
cells were split into 10 cm dishes and grown for 24 h. Next day, cells were trans-
fected AXL-FLAG (105933, Addgene, Watertown, USA) and of BMPR2-Myc
plasmids using Turbofect transfection reagent (R0531, Thermo Scientific, Massa-
chusetts, USA) as per manufacturer’s instructions. Cells were washed with ice-cold
DPBS without Ca and Mg (P04-36500, PAN Biotech, Aidenbach, Germany) 24 h
post-transfection. Lysates were collected using IP lysis buffer (87787, Thermo
Fisher Scientific, Waltham, USA) with the addition of Phenylmethylsulfonyl
Fluoride (PMSF), Sodium Fluoride (NaF), Sodium Orthovanadate (Na3VO4), and
cOmplete™ EDTA-free Protease Inhibitor Cocktail PIC (11836170001 Roche, Basel,
Switzerland). Preclearing was performed with addition of 30 µl of protein A/G plus
Agarose beads and IgG antibody for 1 h rotation at 4 °C. Then, 10% of protein
lysate was separated for whole-cell lysates (WCL) and 700 µg of the total protein
was used for immunoprecipitations. Lysates were incubated either with FLAG
antibody, targeting Axl (1 µl per 50 µl of total protein) (F1804, Sigma-Aldrich
Chemie GmbH, Munich, Germany) or with BMPR2 antibody (10 µg per 1 mg of
total protein) (sc-393304, Santa Cruz Biotechnology, Dallas, USA) for 1 h rotation
at 4 °C. After 1 h of incubation, 40 µl of protein A/G-agarose beads was added to
the antibody–lysate mixture and left overnight for rotation at 4 °C. Next day, the
beads were washed with ice-cold IP lysis buffer and twice with PBS. Beads were
boiled in 50 ml of 4X LDS sample buffer and 10X NuPAGE Sample Reducing
Agent and the and solubilized material underwent gel electrophoresis and western
blot analysis. For immunoprecipitation of hPAECs, cells were split into 10 cm
dishes and grown for 48 h in EGM-2 medium. After overnight incubation, cells
were washed with ice-cold DPBS without Ca and Mg (P04-36500, PAN Biotech,
Aidenbach, Germany) and lysed in IP lysis buffer. Lysis was performed by passing
the lysates through the needle (20 G). The lysates were incubated with BMPR2 IP
antibody (10 µg per 1 mg of protein), as described above. As a negative control, the
pull down with IgG1 antibody (10 µg per 1 mg of protein) (sc-2025, Santa Cruz
Biotechnology, Dallas, USA) was performed.
Immunohistostaining and immunofluorescence. Explanted human and rat lungs
were flushed with saline, fixed in 4% PFA, and washed in PBS before dehydrations.
Then the lungs were embedded in paraffin and 2–3 μm thick sections were
obtained, hematoxylin/eosin staining and immunohistochemistry were performed
with a microtome. From the rat studies, the left lobe of the lung was utilized for the
paraffin embedding. Axl receptor has been detected on rat sections by the
immunohistochemistry with the antibody from Antibodies Online (ABIN756022,
Aachen, Germany) and on rat sections using the antibody purchased from Cell
Signaling (C89E7); macrophages have been stained with monoclonal anti-CD68
antibody clone ED1 (MCA341GA, Bio-Rad Laboratories GmbH, Feldkirchen,
Germany). For antigen retrieval after dehydration, rat lung blocks were cooked in
rodent decloaker (Biocare medical by Zytomed Systems GmbH). For blocking of
endogenous rat IgG and non-specific background in rat tissues, Rodent block R has
been utilized (Biocare medical by Zytomed Systems GmbH). For antigen retrieval
of human sections, Tris-EDTA (pH 9.0) or Citrate buffer (pH 6.0) were applied.
After overnight incubation with all the antibodies, stained sections were extensively
washed in either PBS or TBS, and antibody binding was determined using the
ZytoChem Plus phosphatase polymer kit (Zytomed Systems GmbH, Berlin, Ger-
many). The Warp Red Chromogen substrate kit (Zytomed Systems GmbH) was
used where positive stain was in purple. The assessment of the medial wall
thickness and the ratio of neointima/media was achieved by Elastica-van-Gieson
staining. All the arteries were categorized according to their external diameter
using a computerized morphometric analysis system (QWin: Leica, Wetzlar,
Germany). Small arteries included those with an external diameter between 20 and
50 μm that have been used for the quantitative analyses. All the pulmonary vessels
per each lung with a diameter of 20–50 µm were analyzed with a microscope at a
63-fold magnification. The medial wall thickness was calculated by using the fol-
lowing formula MWT= (2 ×WT/EVD) × 100, where WT is wall thickness (the
mean distance between the lamina elastic externa and the vessel lumen) and EVD
is external vessel diameter. For the analyses of neointima/media ratio, neointima,
the cellular layer between the lamina elastic interna and the pulmonary vessel
lumen was divided by the media, the area between the lamina elastica interna and
the lamina elastica externa. For double immunofluorescence staining of human
lung cryopreserved sections, anti-goat Axl antibody (AF854, R&D Systems, Min-
neapolis, USA) was combined with anti-mouse α-SMA antibody (clone 1A4)
(F3777, Sigma-Aldrich, St. Louis, USA) or anti-rabbit von Willebrand factor (vWF)
(ab9378, Abcam, Cambridge, UK). For immunofluorescence staining of PMVECs,
the Isolectin GS-IB4 (from Griffonia simplicifolia) (I21411, Thermo Fisher Scien-
tific, Waltham, USA) was applied.
Permeability assay. Human PAECs were split at 25,000 cells per insert. Cells were
grown for several days in EGM-2 at 37 °C and 5% of CO2. The medium was
changed every second day. After cell confluency was reached, hPAECs were starved
for 24 h in Endothelial Cell Basal Medium with the addition of 0.2% FCS. Fol-
lowing serum-starvation, cells were treated with R428 (1 µM), or TNF-α (5 ng/ml),
or DMSO for the subsequent 24 h. Inserts were then transferred to a new receiver
tray and a working solution of FITC-Dextran (1:40 diluted in the medium)
(ECM644; Millipore, Bedford, MA) was added to the top chamber. Thereafter, light
protected incubation was continued. Inserts were temporarily removed to another
tray and 100 µl was taken to a special black 96-well opaque plate for fluorescence
measurement. To determine the absorbance at the desired wavelengths (an exci-
tation 485 nm and emission 535 nm), samples were measured every 6 h using an
Infinite M200 Pro instrument from Tecan Group (Männedorf, Switzerland).
Experiments were performed in quadruplicate.
Western blot. Total protein from rat lung tissues was extracted using cell lysis
buffer (Cell Signaling Technology, MA, USA) using the TissueLyser LT (Qiagen,
Germany) for homogenization of the samples. Protein lysates from human
PASMCs and PAECs were isolated using RIPA buffer (Thermo Fisher Scientific).
Both buffers contained protease and phosphatase inhibitors (Calbiochem, Carls-
bad, Germany). After centrifugation at 12,000g for 10 min at 4 °C, protein con-
centration was estimated and normalized using a Bio-Rad protein assay kit (Bio-
Rad Laboratories, Hercules, CA, USA). After denaturation for 10 min at 95 °C,
equal amounts of protein (50 µg) were boiled in the presence of NuPAGE LDS
Sample Buffer and NuPAGE Reducing Reagent and loaded on to 4–12% NuPage
Bis-Tris Gels (Invitrogen, Carlsbad, CA, USA). Gel electrophoresis was followed by
transfer to nitrocellulose membrane. Blocking was performed in 5% non-fat dry
milk dissolved in 1% TBS/Tween-20 (TBS/T) at RT. Primary antibodies were
incubated for overnight at 4 °C in 5% BSA in 1% TBS/T. All primary antibodies
were diluted in 5% BSA diluted in Tris-buffered saline/Tween-20 for 1 h at room
temperature and then incubated with primary antibodies at 4 °C overnight with
gentle agitation. All primary antibodies used for western blot analyses are repre-
sented in Supplementary Table 1.
Amersham HRP-labeled secondary antibodies. The ECL Mouse IgG, HRP-linked
whole Ab from sheep (NA931) and the ECL Rabbit IgG, HRP-linked whole Ab
from donkey (NA934) purchased from GE Healthcare (Little Chalfont, Buck-
inghamshire, England) were diluted 1:10,000 in 5% non-fat dry milk (T145.3, Carl
Roth, Karlsruhe, Germany) in 1% TBS/T. The Anti Goat IgG HRP antibody was
obtained from Sigma-Aldrich (A8919, Sigma-Aldrich, St. Louis, USA). After 1 h of
incubation at RT and washing in 1% TBS/T, the membranes were incubated in ECL
Prime Western Blot Detection Solution (GE Healthcare, Little Chalfont, and
Buckinghamshire, England) for visualization of the protein bands.
RNA isolation, cDNA synthesis, quantitative RT-PCR. Total RNA from rat lung
tissues was isolated using TRIzol reagent (Thermo Fisher Scientific, Waltham,
USA) according to the manufacturer’s protocol. RNA from PASMCs and PAECs
was isolated using the RNeasy Kit (Qiagen, Hilden, Germany) including an on-
column DNase digest step according to the manufacturer’s protocol. RNA con-
centration was measured via Nanodrop ND1000 (Thermo Fisher Scientific). cDNA
was generated by standard reverse transcription that was performed including 1 µg
RNA, dNTPs, Random Hexamer Primer (Thermo Fisher Scientific, Waltham, US
SO142), and M-MLV reverse transcriptase (Ambion, Austin, US, AM2044) in a
thermocycler. The PCR products were detected on 96-well plates, PCR was per-
formed on an Mx3000P® qPCR System machine (Stratagene, Agilent Technologies,
Waldbronn, Germany) using iTaq™ Universal SYBR® Green Supermix (Bio-Rad
Laboratories, Hercules, CA, USA), primers (Metabion International AG, Planegg/
Steinkirchen, München, Germany), RNAse-free water (Qiagen, Hilden, Germany),
and 1 µl of cDNA samples. Ct values were normalized to the reference genes
GAPDH, 18S, HPRT, and B2M and relative gene expression was calculated on the
basis of ΔCt values. The ΔCt values for each target gene were calculated by
ΔCt= Cthousekeeping gene−Cttarget gene. Each gene was normalized to a housekeeping
control as indicated. Primer sequences used for quantitative real-time PCR analyses
are represented in Supplementary Table 2.
ELISAs and TUNEL. All the enzyme-linked immunosorbent assays for the study
were performed according to manufacturer’s instructions. The In Situ Cell Death
Detection Kit TMR red has been utilized for the paraffin-embedded (3 µm) thick
rat lung sections following the recommendations by the company (12156792910,
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Roche, Basel, Switzerland). Recombinant proteins and ELISA kits used for the
study are represented in Supplementary Table 3.
Animal experiments. All animal experiments were approved by the local autho-
rities and the federal authorities for animal research of the Regierungspräsidium
Giessen (approval numbers: GI 20/10 Nr. G 50/2016 and GI 20/10 Nr.33/3013).
Adult male Wistar-Kyoto rats (220–250 g body weight) and adult male Sprague-
Dawley rats (300–350 g body weight) were obtained from Charles River GmbH
(Sulzfeld, Germany). For the MCT model of PH, Sprague-Dawley rats were sub-
cutaneously injected with MCT (60 mg/kg body weight) and randomized on day 21
to receive a daily dose of R428 (100 mg/kg body weight) or vehicle (1% of
methylcellulose) by oral gavage during the subsequent 2 weeks. Rats injected with
saline instead of MCT on day 0 were used as healthy controls. For the Sugen 5416
hypoxia (SuHOX) rat model of PH, Wistar-Kyoto rats were injected with Sugen
5416 (20 mg/kg body weight) and kept in hypoxic chambers (10% oxygen). After
3 weeks of hypoxic exposure, rats were re-exposed to normoxic conditions for 2
additional weeks and randomized to receive a daily dose of R428 (100 mg/kg body
weight) or vehicle by oral gavage. Rats injected with vehicle (100% dimethyl
sulfoxide) were used as hypoxic controls. Transthoracic echocardiography was
performed with the Vevo 2100 system (VisualSonics, Toronto, Canada) equipped
with an 18–38MHz transducer (MS400, for mouse cardiovascular assessment).
Measurement of RVSP and systemic arterial pressure was performed as described
previously66,67.
Statistics and reproducibility. Statistical analysis was performed using Prism 8.00
(GraphPad, San Diego, CA, USA). Biological replicates are defined as different
animals or cultured cells under the same experimental conditions but processed in
parallel. Independent cell culture experiments are defined as different sets of cells
processed at different times. No statistics were derived from technical replicates. All
data are expressed as mean ± SEM. For comparison of two groups, Student’s t-test
was applied; for comparisons involving more than two groups, one-way analyses of
variance corrected by Tukey’s or Newman-Keuls post hoc tests were applied.
P < 0.05 was considered statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data generated in this study are included in the article (and its Supplementary Data
files). Source data for figures and supplementary figures can be found in Supplementary
Data 1. Original blots/gel images are shown in Supplementary Data 2. The data
underlying all findings of this study are available from the corresponding author upon
reasonable request and are provided as a separate source data file.
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